vs

Side-by-side financial comparison of Arcellx, Inc. (ACLX) and Broadway Financial Corp (BYFC). Click either name above to swap in a different company.

Broadway Financial Corp is the larger business by last-quarter revenue ($9.4M vs $8.1M, roughly 1.2× Arcellx, Inc.). Broadway Financial Corp runs the higher net margin — 1934.0% vs -766.0%, a 2700.0% gap on every dollar of revenue. On growth, Broadway Financial Corp posted the faster year-over-year revenue change (10.1% vs -79.3%). Broadway Financial Corp produced more free cash flow last quarter ($-13.0K vs $-63.9M). Over the past eight quarters, Broadway Financial Corp's revenue compounded faster (9.7% CAGR vs -24.6%).

Arcellx, Inc. is a clinical-stage biotechnology company that develops innovative chimeric antigen receptor T (CAR-T) cell therapies for treating hard-to-treat cancers including hematologic malignancies and solid tumors. Its core pipeline targets unmet oncology medical needs, serving global patient populations and partnering with life sciences stakeholders.

Virtu Financial, Inc. is an American high-frequency trading company. The company went public on the Nasdaq in 2015.

ACLX vs BYFC — Head-to-Head

Bigger by revenue
BYFC
BYFC
1.2× larger
BYFC
$9.4M
$8.1M
ACLX
Growing faster (revenue YoY)
BYFC
BYFC
+89.4% gap
BYFC
10.1%
-79.3%
ACLX
Higher net margin
BYFC
BYFC
2700.0% more per $
BYFC
1934.0%
-766.0%
ACLX
More free cash flow
BYFC
BYFC
$63.9M more FCF
BYFC
$-13.0K
$-63.9M
ACLX
Faster 2-yr revenue CAGR
BYFC
BYFC
Annualised
BYFC
9.7%
-24.6%
ACLX

Income Statement — Q1 FY2025 vs Q4 FY2025

Metric
ACLX
ACLX
BYFC
BYFC
Revenue
$8.1M
$9.4M
Net Profit
$-62.3M
$1.0M
Gross Margin
Operating Margin
-847.6%
Net Margin
-766.0%
1934.0%
Revenue YoY
-79.3%
10.1%
Net Profit YoY
-765.1%
-21.8%
EPS (diluted)
$-1.13
$0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACLX
ACLX
BYFC
BYFC
Q4 25
$9.4M
Q3 25
$9.0M
Q2 25
$8.1M
Q1 25
$8.1M
$8.3M
Q4 24
$15.3M
$8.6M
Q3 24
$26.0M
$8.7M
Q2 24
$27.4M
$8.2M
Q1 24
$39.3M
$7.8M
Net Profit
ACLX
ACLX
BYFC
BYFC
Q4 25
$1.0M
Q3 25
$-23.9M
Q2 25
$752.0K
Q1 25
$-62.3M
$-2.7M
Q4 24
$-47.1M
$1.3M
Q3 24
$-25.9M
$516.0K
Q2 24
$-27.2M
$256.0K
Q1 24
$-7.2M
$-154.0K
Operating Margin
ACLX
ACLX
BYFC
BYFC
Q4 25
Q3 25
-256.2%
Q2 25
12.8%
Q1 25
-847.6%
-45.3%
Q4 24
-348.2%
21.7%
Q3 24
-129.1%
8.5%
Q2 24
-127.8%
4.8%
Q1 24
-40.3%
-2.9%
Net Margin
ACLX
ACLX
BYFC
BYFC
Q4 25
1934.0%
Q3 25
-264.2%
Q2 25
9.3%
Q1 25
-766.0%
-32.3%
Q4 24
-308.4%
15.3%
Q3 24
-99.4%
5.9%
Q2 24
-99.3%
3.1%
Q1 24
-18.3%
-2.0%
EPS (diluted)
ACLX
ACLX
BYFC
BYFC
Q4 25
$0.02
Q3 25
$-2.86
Q2 25
$0.00
Q1 25
$-1.13
$-0.39
Q4 24
$-0.87
$0.07
Q3 24
$-0.48
$-0.03
Q2 24
$-0.51
$0.02
Q1 24
$-0.14
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACLX
ACLX
BYFC
BYFC
Cash + ST InvestmentsLiquidity on hand
$543.3M
$10.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$416.9M
$262.8M
Total Assets
$648.1M
$1.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACLX
ACLX
BYFC
BYFC
Q4 25
$10.5M
Q3 25
$19.7M
Q2 25
$29.5M
Q1 25
$543.3M
$15.8M
Q4 24
$587.4M
$61.4M
Q3 24
$574.3M
$97.1M
Q2 24
$516.7M
$89.8M
Q1 24
$573.9M
$67.1M
Stockholders' Equity
ACLX
ACLX
BYFC
BYFC
Q4 25
$262.8M
Q3 25
$261.7M
Q2 25
$284.7M
Q1 25
$416.9M
$283.6M
Q4 24
$454.8M
$285.0M
Q3 24
$483.0M
$286.2M
Q2 24
$487.2M
$282.1M
Q1 24
$496.6M
$281.1M
Total Assets
ACLX
ACLX
BYFC
BYFC
Q4 25
$1.3B
Q3 25
$1.3B
Q2 25
$1.2B
Q1 25
$648.1M
$1.3B
Q4 24
$711.3M
$1.3B
Q3 24
$764.9M
$1.4B
Q2 24
$734.3M
$1.4B
Q1 24
$779.7M
$1.4B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACLX
ACLX
BYFC
BYFC
Operating Cash FlowLast quarter
$-63.1M
$230.0K
Free Cash FlowOCF − Capex
$-63.9M
$-13.0K
FCF MarginFCF / Revenue
-786.4%
-0.1%
Capex IntensityCapex / Revenue
9.6%
2.6%
Cash ConversionOCF / Net Profit
0.22×
TTM Free Cash FlowTrailing 4 quarters
$-122.5M
$2.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACLX
ACLX
BYFC
BYFC
Q4 25
$230.0K
Q3 25
$3.8M
Q2 25
$3.0M
Q1 25
$-63.1M
$-4.3M
Q4 24
$-46.0M
$1.4M
Q3 24
$30.7M
$6.1M
Q2 24
$-36.2M
$9.8M
Q1 24
$-31.9M
$-11.7M
Free Cash Flow
ACLX
ACLX
BYFC
BYFC
Q4 25
$-13.0K
Q3 25
$3.7M
Q2 25
$3.0M
Q1 25
$-63.9M
$-4.4M
Q4 24
$-47.5M
$1.3M
Q3 24
$28.4M
$6.1M
Q2 24
$-39.5M
$9.7M
Q1 24
$-38.3M
$-11.7M
FCF Margin
ACLX
ACLX
BYFC
BYFC
Q4 25
-0.1%
Q3 25
41.1%
Q2 25
37.0%
Q1 25
-786.4%
-52.4%
Q4 24
-311.3%
14.7%
Q3 24
109.2%
69.6%
Q2 24
-144.1%
118.9%
Q1 24
-97.7%
-149.7%
Capex Intensity
ACLX
ACLX
BYFC
BYFC
Q4 25
2.6%
Q3 25
1.2%
Q2 25
0.2%
Q1 25
9.6%
0.2%
Q4 24
9.8%
1.6%
Q3 24
8.8%
0.3%
Q2 24
11.7%
0.5%
Q1 24
16.4%
0.7%
Cash Conversion
ACLX
ACLX
BYFC
BYFC
Q4 25
0.22×
Q3 25
Q2 25
4.00×
Q1 25
Q4 24
1.06×
Q3 24
11.85×
Q2 24
38.21×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons